Abstract
Diabetic kidney disease (DKD), the most common cause of end-stage kidney disease (ESKD), has significant morbidity and mortality, particularly from cardiovascular complications. The CREDENCE (canagliflozin and renal events in diabetes with established nephropathy clinical evaluation) trial reported by Perkovic and collaborators has led to an emergence of a new class of therapeutic agents for slowing DKD progression.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
